Altus Pharmaceuticals Inc. Form 8-K March 12, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):	March 9, 2009

Altus Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-51711	04-3573277
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
333 Wyman Street, Waltham, Massachusetts		02451
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including	781-373-6000	
	Not Applicable	
Former na	me or former address, if changed since l	ast report
Check the appropriate box below if the Form 8-K filing he following provisions:	ng is intended to simultaneously satisfy	the filing obligation of the registrant under any of
 Written communications pursuant to Rule 425 un Soliciting material pursuant to Rule 14a-12 under Pre-commencement communications pursuant to Pre-commencement communications pursuant to 	r the Exchange Act (17 CFR 240.14a-12 Rule 14d-2(b) under the Exchange Act	2) (17 CFR 240.14d-2(b))

Edgar Filing: Altus Pharmaceuticals Inc. - Form 8-K

Top	of	the	e Fo	rm	
					Events.

On March 9, 2009, Philip Gotwals, Ph.D., informed Altus Pharmaceuticals Inc. (the "Company") that he plans to resign as the Vice President, Program Management of the Company effective March 25, 2009 to pursue an opportunity at another company.

Edgar Filing: Altus Pharmaceuticals Inc. - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Altus Pharmaceuticals Inc.

March 12, 2009 By: Jonathan I. Lieber

Name: Jonathan I. Lieber

Title: Senior Vice President, Chief Financial Officer and

Treasurer